Profiling the cancer genome to optimize the management of solid tumors 

Accurate detection of molecular signatures associated with solid tumors is difficult. It requires multiple cytogenetic and molecular assays that can be costly and time-consuming.1

 

Three solutions tailored to your needs

SOPHiA Solid Tumor

SOPHiA Solid Tumor Solution (STS) is a CE-IVD registered genomic application that covers 42 genes associated with a range of solid tumors and offers advanced performance in detecting SNVs/Indels, MSI and CNVs.

SOPHiA Solid Tumor Plus

SOPHiA Solid Tumor Plus Solution (STS+) extends the characterization of the mutational landscape offered in STS by adding the ability to detect the RNA transcripts of 137 gene fusions without sacrificing multiplexing.

TST170 powered by SOPHiA

TST170 powered by SOPHiA is a fully integrated (FASTQ-to-Report) bioinformatics workflow that works in tandem with the TruSight™ 170 panel in pan-cancer genomic profiling. The TST170 workflow offers enhanced analytical performance and accelerated variant interpretation.

1:Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection.Phillip N. Gray,*Charles L.M. Dunlop et al. Cancers (Basel). 2015 Sep; 7(3): 1313–1332.

All product and company names are trademarks or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

SOPHiA Solid Tumor Solution is a CE-IVD products for Europe only. All other products including the SOPHiA DDM platform provided in Europe are Research Use Only.